LY-334,370

LY-334,370
Nazivi
	IUPAC naziv 4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]benzamide
	Drugi nazivi LY-334,370
Identifikacija
CAS broj	182563-08-2;
3D model (Jmol)	interaktivna slika;
IUPHAR/BPS	20;
PubChem C ID	5311258;
	SMILES CN1CCC(c2c3cc(N([H])C(c4ccc(F)cc4)=O)ccc3n([H])c2)CC1; ; ; ; ; ;
Svojstva
Hemijska formula	C21H22FN3O
Molarna masa	351,42 g/mol
	Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje materijala (na 25 °C [77 °F], 100 kPa).
	verifikuj (šta je ?)
	Reference infokutije

LY-334,370 je selektivni agonist 5-HT_1F receptora^[3] koga razvija Eli Lili i kompanija za lečenje migrenske glavobolje.^[4] Lek je pokazao efikasnost u fazi II kliničkih ispitivanja,^[5] ali je dalji razvoj zaustavljen usled ustanovljene toksičnosti u životinjskim ispitivanjima.^[6]

Vidi još уреди

Lasmiditan, 5-HT_1F agonist za lečenje migrene

Literatura уреди

^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди
^ Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.
^ Dupuis DS, Colpaert FC, Pauwels PJ (1998). „G-protein activation at 5-HT_1A receptors by the 5-HT_1F ligand LY-334,370 in guinea-pig brain sections and recombinant cell lines”. Br. J. Pharmacol. 124 (2): 283—90. PMID 9641544. doi:10.1038/sj.bjp.0701832.
^ Shepheard S, Edvinsson L, Cumberbatch M, Williamson D, Mason G, Webb J, Boyce S, Hill R, Hargreaves R (1999). „Possible antimigraine mechanisms of action of the 5HT_1F receptor agonist LY-334,370”. Cephalalgia. 19 (10): 851—8. PMID 10668103. doi:10.1046/j.1468-2982.1999.1910851.x.
^ Goldstein DJ, Roon KI, Offen WW, Ramadan NM, Phebus LA, Johnson KW, Schaus JM, Ferrari MD (2001). „Selective seratonin 1F (5-HT_1F) receptor agonist LY334370 for acute migraine: a randomised controlled trial”. Lancet. 358 (9289): 1230—4. PMID 11675061. doi:10.1016/S0140-6736(01)06347-4.
^ Ramadan NM, Buchanan TM (2006). „New and future migraine therapy”. Pharmacol. Ther. 112 (1): 199—212. PMID 16797716. doi:10.1016/j.pharmthera.2005.04.010.

Spoljašnje veze уреди

4-fluoro-N-(3-(1-methyl-4-piperidinyl)-1H-indol-5-yl)benzamide на US National Library of Medicine Medical Subject Headings (MeSH)

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди

[2] Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.

[pmid9641544-3] Dupuis DS, Colpaert FC, Pauwels PJ (1998). „G-protein activation at 5-HT_1A receptors by the 5-HT_1F ligand LY-334,370 in guinea-pig brain sections and recombinant cell lines”. Br. J. Pharmacol. 124 (2): 283—90. PMID 9641544. doi:10.1038/sj.bjp.0701832.

[pmid10668103-4] Shepheard S, Edvinsson L, Cumberbatch M, Williamson D, Mason G, Webb J, Boyce S, Hill R, Hargreaves R (1999). „Possible antimigraine mechanisms of action of the 5HT_1F receptor agonist LY-334,370”. Cephalalgia. 19 (10): 851—8. PMID 10668103. doi:10.1046/j.1468-2982.1999.1910851.x.

[pmid11675061-5] Goldstein DJ, Roon KI, Offen WW, Ramadan NM, Phebus LA, Johnson KW, Schaus JM, Ferrari MD (2001). „Selective seratonin 1F (5-HT_1F) receptor agonist LY334370 for acute migraine: a randomised controlled trial”. Lancet. 358 (9289): 1230—4. PMID 11675061. doi:10.1016/S0140-6736(01)06347-4.

[pmid16797716-6] Ramadan NM, Buchanan TM (2006). „New and future migraine therapy”. Pharmacol. Ther. 112 (1): 199—212. PMID 16797716. doi:10.1016/j.pharmthera.2005.04.010.

[3]

[4]

[5]

[6]

[1]

[2]